Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma
Background: Despite significant advancements in the treatment of malignant melanoma, metastatic mucosal melanoma remains a therapeutic challenge due to its complex pathogenesis, distinct pathological characteristics, and limited response to immunotherapy. Combining different immunotherapeutic approa...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Immuno-Oncology and Technology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590018824000236 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846115910167822336 |
|---|---|
| author | T.J. Monberg T. Kudling B. Albieri S. Pakola E. Ellebaek M. Donia R.L. Eefsen C. von Buchwald C. Kistler J.M. Santos J. Clubb L. Haybout M.C.W. Westergaard D.C.A. Quixabeira E. Jirovec R. Havunen S. Sorsa V. Cervera-Carrascon A. Hemminki I.M. Svane |
| author_facet | T.J. Monberg T. Kudling B. Albieri S. Pakola E. Ellebaek M. Donia R.L. Eefsen C. von Buchwald C. Kistler J.M. Santos J. Clubb L. Haybout M.C.W. Westergaard D.C.A. Quixabeira E. Jirovec R. Havunen S. Sorsa V. Cervera-Carrascon A. Hemminki I.M. Svane |
| author_sort | T.J. Monberg |
| collection | DOAJ |
| description | Background: Despite significant advancements in the treatment of malignant melanoma, metastatic mucosal melanoma remains a therapeutic challenge due to its complex pathogenesis, distinct pathological characteristics, and limited response to immunotherapy. Combining different immunotherapeutic approaches offers a potential strategy to address these challenges. Tumor-infiltrating lymphocyte (TIL) therapy and oncolytic virus therapy represent promising treatment modalities that may synergize with each other. Patient and methods: We present a case of a 48-year-old woman with metastatic sinonasal mucosal melanoma who achieved a durable complete pathological response following treatment with multiple injections of the oncolytic virus TILT-123 (igrelimogene litadenorepvec) and a single infusion of TILs, without preconditioning chemotherapy or postconditioning interleukin-2. Results: Immunohistochemical analysis and single-cell sequencing revealed interesting alterations in injected and noninjected tumors as well as in peripheral blood, during the treatment course, suggesting that TILT-123 facilitated TIL engraftment into the tumor, ultimately leading to a complete response. Conclusions: This case underscores the potential of combined immunotherapeutic approaches as a promising strategy for patients with metastatic mucosal melanoma. |
| format | Article |
| id | doaj-art-c2a2b8dacdf84216a4a29c542b214c6c |
| institution | Kabale University |
| issn | 2590-0188 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Immuno-Oncology and Technology |
| spelling | doaj-art-c2a2b8dacdf84216a4a29c542b214c6c2024-12-19T10:56:50ZengElsevierImmuno-Oncology and Technology2590-01882024-12-0124100726Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanomaT.J. Monberg0T. Kudling1B. Albieri2S. Pakola3E. Ellebaek4M. Donia5R.L. Eefsen6C. von Buchwald7C. Kistler8J.M. Santos9J. Clubb10L. Haybout11M.C.W. Westergaard12D.C.A. Quixabeira13E. Jirovec14R. Havunen15S. Sorsa16V. Cervera-Carrascon17A. Hemminki18I.M. Svane19National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, DenmarkCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, FinlandNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, DenmarkCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, FinlandNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, DenmarkNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, DenmarkNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, DenmarkDepartment of ORL, Head and Neck Surgery and Audiology, Copenhagen University Hospital, Rigshospitalet, DenmarkTILT Biotherapeutics Ltd, HelsinkiCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Ltd, HelsinkiCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Ltd, HelsinkiCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Ltd, HelsinkiNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, DenmarkCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Ltd, HelsinkiCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, FinlandCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Ltd, HelsinkiCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Ltd, HelsinkiCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Ltd, HelsinkiCancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Ltd, Helsinki; Helsinki University Hospital Comprehensive Cancer Center, Helsinki, FinlandNational Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark; Correspondence to: Prof. Inge Marie Svane, National Center for Cancer Immune Therapy (CCIT-DK), Herlev Hospital, Borgmester Ib Juuls Vej 13, 2730 Herlev, Denmark. Tel: +45-38-68-21-31Background: Despite significant advancements in the treatment of malignant melanoma, metastatic mucosal melanoma remains a therapeutic challenge due to its complex pathogenesis, distinct pathological characteristics, and limited response to immunotherapy. Combining different immunotherapeutic approaches offers a potential strategy to address these challenges. Tumor-infiltrating lymphocyte (TIL) therapy and oncolytic virus therapy represent promising treatment modalities that may synergize with each other. Patient and methods: We present a case of a 48-year-old woman with metastatic sinonasal mucosal melanoma who achieved a durable complete pathological response following treatment with multiple injections of the oncolytic virus TILT-123 (igrelimogene litadenorepvec) and a single infusion of TILs, without preconditioning chemotherapy or postconditioning interleukin-2. Results: Immunohistochemical analysis and single-cell sequencing revealed interesting alterations in injected and noninjected tumors as well as in peripheral blood, during the treatment course, suggesting that TILT-123 facilitated TIL engraftment into the tumor, ultimately leading to a complete response. Conclusions: This case underscores the potential of combined immunotherapeutic approaches as a promising strategy for patients with metastatic mucosal melanoma.http://www.sciencedirect.com/science/article/pii/S2590018824000236case reportmucosal melanomatumor-infiltrating lymphocytesoncolytic virus therapy |
| spellingShingle | T.J. Monberg T. Kudling B. Albieri S. Pakola E. Ellebaek M. Donia R.L. Eefsen C. von Buchwald C. Kistler J.M. Santos J. Clubb L. Haybout M.C.W. Westergaard D.C.A. Quixabeira E. Jirovec R. Havunen S. Sorsa V. Cervera-Carrascon A. Hemminki I.M. Svane Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma Immuno-Oncology and Technology case report mucosal melanoma tumor-infiltrating lymphocytes oncolytic virus therapy |
| title | Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma |
| title_full | Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma |
| title_fullStr | Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma |
| title_full_unstemmed | Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma |
| title_short | Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma |
| title_sort | durable complete response after combined treatment with tumor infiltrating lymphocytes and oncolytic adenovirus tilt 123 in a patient with metastatic mucosal melanoma |
| topic | case report mucosal melanoma tumor-infiltrating lymphocytes oncolytic virus therapy |
| url | http://www.sciencedirect.com/science/article/pii/S2590018824000236 |
| work_keys_str_mv | AT tjmonberg durablecompleteresponseaftercombinedtreatmentwithtumorinfiltratinglymphocytesandoncolyticadenovirustilt123inapatientwithmetastaticmucosalmelanoma AT tkudling durablecompleteresponseaftercombinedtreatmentwithtumorinfiltratinglymphocytesandoncolyticadenovirustilt123inapatientwithmetastaticmucosalmelanoma AT balbieri durablecompleteresponseaftercombinedtreatmentwithtumorinfiltratinglymphocytesandoncolyticadenovirustilt123inapatientwithmetastaticmucosalmelanoma AT spakola durablecompleteresponseaftercombinedtreatmentwithtumorinfiltratinglymphocytesandoncolyticadenovirustilt123inapatientwithmetastaticmucosalmelanoma AT eellebaek durablecompleteresponseaftercombinedtreatmentwithtumorinfiltratinglymphocytesandoncolyticadenovirustilt123inapatientwithmetastaticmucosalmelanoma AT mdonia durablecompleteresponseaftercombinedtreatmentwithtumorinfiltratinglymphocytesandoncolyticadenovirustilt123inapatientwithmetastaticmucosalmelanoma AT rleefsen durablecompleteresponseaftercombinedtreatmentwithtumorinfiltratinglymphocytesandoncolyticadenovirustilt123inapatientwithmetastaticmucosalmelanoma AT cvonbuchwald durablecompleteresponseaftercombinedtreatmentwithtumorinfiltratinglymphocytesandoncolyticadenovirustilt123inapatientwithmetastaticmucosalmelanoma AT ckistler durablecompleteresponseaftercombinedtreatmentwithtumorinfiltratinglymphocytesandoncolyticadenovirustilt123inapatientwithmetastaticmucosalmelanoma AT jmsantos durablecompleteresponseaftercombinedtreatmentwithtumorinfiltratinglymphocytesandoncolyticadenovirustilt123inapatientwithmetastaticmucosalmelanoma AT jclubb durablecompleteresponseaftercombinedtreatmentwithtumorinfiltratinglymphocytesandoncolyticadenovirustilt123inapatientwithmetastaticmucosalmelanoma AT lhaybout durablecompleteresponseaftercombinedtreatmentwithtumorinfiltratinglymphocytesandoncolyticadenovirustilt123inapatientwithmetastaticmucosalmelanoma AT mcwwestergaard durablecompleteresponseaftercombinedtreatmentwithtumorinfiltratinglymphocytesandoncolyticadenovirustilt123inapatientwithmetastaticmucosalmelanoma AT dcaquixabeira durablecompleteresponseaftercombinedtreatmentwithtumorinfiltratinglymphocytesandoncolyticadenovirustilt123inapatientwithmetastaticmucosalmelanoma AT ejirovec durablecompleteresponseaftercombinedtreatmentwithtumorinfiltratinglymphocytesandoncolyticadenovirustilt123inapatientwithmetastaticmucosalmelanoma AT rhavunen durablecompleteresponseaftercombinedtreatmentwithtumorinfiltratinglymphocytesandoncolyticadenovirustilt123inapatientwithmetastaticmucosalmelanoma AT ssorsa durablecompleteresponseaftercombinedtreatmentwithtumorinfiltratinglymphocytesandoncolyticadenovirustilt123inapatientwithmetastaticmucosalmelanoma AT vcerveracarrascon durablecompleteresponseaftercombinedtreatmentwithtumorinfiltratinglymphocytesandoncolyticadenovirustilt123inapatientwithmetastaticmucosalmelanoma AT ahemminki durablecompleteresponseaftercombinedtreatmentwithtumorinfiltratinglymphocytesandoncolyticadenovirustilt123inapatientwithmetastaticmucosalmelanoma AT imsvane durablecompleteresponseaftercombinedtreatmentwithtumorinfiltratinglymphocytesandoncolyticadenovirustilt123inapatientwithmetastaticmucosalmelanoma |